Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
X4 Pharmaceuticals (XFOR) PT Lowered to $4 at Stifel
November 13, 2024 4:00 PM ESTStifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $4.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "The XOLREMDI launch in WHIM syndrome was always going to be a show-me story for investors and the longer-term opportunity... More
